Trial Profile
A Randomized Controlled Observer Blind Trial to Compare the Immunogenicity and Acceptability of a MF59-adjuvanted Influenza Vaccine Compared to an Inactivated Influenza Vaccine as a Preferred Influenza Vaccine Priming Strategy for Naive Infants 6 to <24 Months of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2022
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; MF 59
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 28 Jan 2022 Status changed from recruiting to completed.
- 11 Aug 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 11 Aug 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.